Syros Pharmaceuticals (SYRS) Misses Q3 EPS by 29c

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q3 EPS of ($1.43), $0.29 worse than the analyst estimate of ($1.14). Revenue for the quarter came in at $3.76 million versus the consensus estimate of $3.94 million.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.

You May Also Be Interested In

• Phoenix Education Partners, Inc. (PXED) Misses Q3 EPS by 14c; Offers Outlook
• Pentair cuts 2026 outlook, names interim CFO after pool slump
• Bank of America (BAC) Tops Q2 EPS by 9c, Beats on Revenue